Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Scopus Biopharma Inc (NASDAQ:SCPS)
|Dividend Rate (ttm)||0.0000|
|Trading Day||Sep 24|
|Day's Range||4.16 - 4.4|
|52 Week Range||4 - 47.86|
Scopus Biopharma Inc dividends
Scopus Biopharma Inc has a market cap or net worth of $76.72 million. The enterprise value is $0.
Scopus Biopharma Inc has 18.09 million shares outstanding.
The trailing PE ratio is 0.0000 and the forward PE ratio is -18.1667. Scopus Biopharma Inc's PEG ratio is 0.0000.
Stock Price Statistics
The stock price has decreased by -0.7062%. The beta is 0.0000, so Scopus Biopharma Inc's price volatility has been lower than the market average.
In the last 12 months, Scopus Biopharma Inc had revenue of $0 and earned $0 in profits. Earnings per share was $.
Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics capitalizing on groundbreaking scientific and medical discoveries from leading research and academic institutions.
The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. This drug candidate is highly distinctive, encompassing both gene therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment.
The company is also developing additional new chemical entities to treat other serious diseases with significant unmet medical needs, including systemic sclerosis..